Chromium picolinate

Chromium picolinate is marketed as a «blood-sugar support». Meta-analyses of HbA1c in type 2 diabetes are inconsistent: some RCTs show a 0.2–0.6 % reduction, others none. Trial quality is low, chromium doses and forms vary, follow-up is short. ADA Standards of Care 2024 and the Spanish redGDPS 2023 do not recommend chromium for type 2 diabetes because of weak and conflicting evidence. Proven options in type 2 diabetes are metformin, GLP-1 agonists, SGLT2 inhibitors, dietary change and physical activity. If chromium was prescribed instead of or in addition to these, consider seeking a second opinion from an endocrinologist.

Chromium picolinate is a supplement marketed as a «fat burner» and sugar-craving remedy. The Cochrane review 2013 pooled 9 RCTs (622 participants) and found a statistically significant but clinically trivial weight loss of about 0.5 kg over 12–16 weeks versus placebo. Evidence quality is low, the effect disappears after stopping the supplement, and long-term safety above 200 mcg/day is not established. USPSTF 2022 does not recommend vitamin or mineral supplements for weight loss or chronic-disease prevention. If chromium picolinate was bought for weight loss, consider seeking a second opinion: caloric deficit, resistance training, and at BMI above 30 GLP-1 medications after physician review are what actually work.